Newswise Feature Channel: Clinical Trials /articles/channels/Clinical Trials This [feature]/[breaking news]/[focus] channel highlights experts, research, and feature stories related to... en-us Copyright 2025 Newswise Newswise Feature Channel: Clinical Trials 115 31 / /images/newswise-logo-rss.gif Volunteer Appreciation Week: Two Standouts Give Time and Talents /articles/volunteer-appreciation-week-two-standouts-give-time-and-talents/?sc=c6502 /articles/volunteer-appreciation-week-two-standouts-give-time-and-talents/?sc=c6502 Mon, 21 Apr 2025 20:00:19 EST Clinical Trials,In the Workplace,Infectious Diseases,Coronavirus Medical News Feature <img src="/legacy/image.php?image=https://content.presspage.com/uploads/2110/f866cf11-d1c5-4cfe-b833-636dcaf67b9d/1920_jody-simon-volunteer-cedars-sinai.jpg?10000&width=100&height=150" alt="Newswise image" />Throughout Volunteer Appreciation Week, April 21-27, Cedars-Sinai is saluting its many outstanding volunteers and looking to add a few more to the corps. /articles/https://content.presspage.com/uploads/2110/f866cf11-d1c5-4cfe-b833-636dcaf67b9d/1920_jody-simon-volunteer-cedars-sinai.jpg?10000,https://content.presspage.com/uploads/2110/56ea1d7d-1eca-4ab2-980a-99d46288dbe5/800_28567-vol-ed-tlc-micheleprince-1868.jpg?x=1744999301378,https://content.presspage.com/uploads/2110/d1ec346c-45b3-4d39-9c23-26a83be4c809/800_stuart-smith-cedars-sinai-volunteers.jpg?x=1744999735181 Cedars-Sinai Moffitt Cancer Center Researchers Present Top Science at AACR Annual Meeting 2025 /articles/moffitt-cancer-center-researchers-present-top-science-at-aacr-annual-meeting-2025/?sc=c6502 /articles/moffitt-cancer-center-researchers-present-top-science-at-aacr-annual-meeting-2025/?sc=c6502 Mon, 21 Apr 2025 09:00:39 EST Cancer,Clinical Trials,Ethics and Research Methods,Healthcare,Medical Meetings,Scientific Meetings Medical News Announcement Researchers from Moffitt Cancer Center will present data on the latest advances in cancer science and medicine at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will take place April 25-30 in Chicago. Follow us @MoffittNews for updates. Moffitt Cancer Center Yale Cancer Center Research Breakthroughs Unveiled at AACR Annual Meeting /articles/smilow-ycc-image/?sc=c6502 /articles/smilow-ycc-image/?sc=c6502 Mon, 21 Apr 2025 08:20:26 EST Cancer,Clinical Trials,Ethics and Research Methods,Healthcare,Public Health,Medical Meetings Medical News Feature Yale Cancer Center (YCC) experts will present at the 2025 American Association of Cancer Research (AACR) Annual Meeting, which kicks off this Friday in Chicago at the McCormick Place Convention Center. As one of the largest global gatherings of cancer experts, the meeting will highlight new cancer treatments and practice-changing clinical trials from around the world. Yale Cancer Center/Smilow Cancer Hospital Roswell Park Researchers to Discuss Recent Discoveries and Critical Issues in Oncology at AACR 2025 /articles/roswell-park-researchers-to-discuss-recent-discoveries-and-critical-issues-in-oncology-at-aacr-2025/?sc=c6502 /articles/roswell-park-researchers-to-discuss-recent-discoveries-and-critical-issues-in-oncology-at-aacr-2025/?sc=c6502 Thu, 17 Apr 2025 20:55:38 EST Cancer,Clinical Trials,Healthcare,Top Hit Stories Medical News Research Results <img src="/legacy/image.php?image=https://www.roswellpark.org//sites/default/files/styles/1600x800/public/2025-04/hutch_250328_tribal-cancer-health-summit-066.jpeg?itok=IY6BlFnm&width=100&height=150" alt="Newswise image" />Researchers from Roswell Park will report their latest findings to colleagues from around the world at the 2025 annual meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois, April 25-30. /articles/https://www.roswellpark.org//sites/default/files/styles/1600x800/public/2025-04/hutch_250328_tribal-cancer-health-summit-066.jpeg?itok=IY6BlFnm Roswell Park Comprehensive Cancer Center Monell Center Study Identifies GLP-1 Therapies as a Possible Treatment for Rare Genetic Disorder Bardet-Biedl Syndrome /articles/monell-center-study-identifies-glp-1-therapies-as-a-possible-treatment-for-rare-genetic-disorder-bardet-biedl-syndrome/?sc=c6502 /articles/monell-center-study-identifies-glp-1-therapies-as-a-possible-treatment-for-rare-genetic-disorder-bardet-biedl-syndrome/?sc=c6502 Thu, 17 Apr 2025 20:45:00 EST Clinical Trials,Diabetes,Genetics,Healthcare,Obesity,Weight Loss,Top Hit Stories,Grant Funded News Medical News Research Results <img src="/legacy/image.php?image=/images/uploads/2025/04/17/68012e4f5001d_CopyofJCIGraphicalAbstractFinal.jpeg&width=100&height=150" alt="Newswise image" />Monell Center investigators identified that GLP-1R agonists, a class of drugs currently used to treat type-2 diabetes and obesity, as a promising therapeutic for managing the metabolic complications associated with Bardet-Biedl Syndrome (BBS), a rare genetic disorder characterized by early-onset obesity, compulsive eating, and cognitive impairments. They used a genetically engineered mouse model of BBS that displayed the hallmark features of the condition. /articles//images/uploads/2025/04/17/68012e4f5001d_CopyofJCIGraphicalAbstractFinal.jpeg Monell Chemical Senses Center Wesley Sundquist Named to TIME's Annual TIME100 List of the 100 Most Influential People in the World /articles/wesley-sundquist-named-to-time-s-annual-time100-list-of-the-100-most-influential-people-in-the-world/?sc=c6502 /articles/wesley-sundquist-named-to-time-s-annual-time100-list-of-the-100-most-influential-people-in-the-world/?sc=c6502 Thu, 17 Apr 2025 13:05:59 EST AIDS and HIV,Clinical Trials,Healthcare,Pharmaceuticals Medical News,Science News Announcement <img src="/legacy/image.php?image=/images/uploads/2025/04/17/680134eaf17d4_Wes-Sundquist-portrait-5.jpg&width=100&height=150" alt="Newswise image" />Research in the Sundquist lab laid the foundations for the development of lenacapavir, a drug that prevents HIV infection with 99.9% to 100% efficacy and could dramatically lower infection rates worldwide. /articles//images/uploads/2025/04/17/680134eaf17d4_Wes-Sundquist-portrait-5.jpg University of Utah Health New Drug Targets Bone Disease by Blocking the Wnt Signaling Pathway /articles/new-drug-targets-bone-disease-by-blocking-the-wnt-signaling-pathway/?sc=c6502 /articles/new-drug-targets-bone-disease-by-blocking-the-wnt-signaling-pathway/?sc=c6502 Wed, 16 Apr 2025 08:10:47 EST All Journal News,Biotech,Bone Health,Clinical Trials,Healthcare Medical News Research Results <img src="/legacy/image.php?image=/images/uploads/2025/04/16/67ff8f4e9ef9a_.png&width=100&height=150" alt="Newswise image" />Sclerosteosis is a rare genetic disorder that causes excessive bone growth, leading to life-altering complications, including hearing loss and facial paralysis. In a promising new breakthrough, researchers have identified a drug called LGK974, which targets the Wnt signaling pathway by inhibiting the enzyme Porcupine. /articles//images/uploads/2025/04/16/67ff8f4e9ef9a_.png Chinese Academy of Sciences Largest Genome-Wide Association Study Uncovers New Drug Targets and Potential Therapies for Osteoarthritis /articles/largest-genome-wide-association-study-uncovers-new-drug-targets-and-potential-therapies-for-osteoarthritis/?sc=c6502 /articles/largest-genome-wide-association-study-uncovers-new-drug-targets-and-potential-therapies-for-osteoarthritis/?sc=c6502 Tue, 15 Apr 2025 18:10:19 EST All Journal News,Biotech,Bone Health,Clinical Trials,Genetics,Nature (journal) Medical News Research Results <img src="/legacy/image.php?image=https://www.medschool.umaryland.edu/media/som/news/2025/Osteoarthritis-Genome-Banner.jpg&width=100&height=150" alt="Newswise image" />Largest Genome-Wide Association Study Uncovers New Drug Targets and Potential Therapies for Osteoarthritis /articles/https://www.medschool.umaryland.edu/media/som/news/2025/Osteoarthritis-Genome-Banner.jpg University of Maryland School of Medicine Combination Therapy Shows Promise for Hard-to-Treat Pancreatic Cancer /articles/combination-therapy-shows-promise-for-hard-to-treat-pancreatic-cancer/?sc=c6502 /articles/combination-therapy-shows-promise-for-hard-to-treat-pancreatic-cancer/?sc=c6502 Tue, 15 Apr 2025 17:30:33 EST FASEB channel,Cancer,Clinical Trials,Genetics,Healthcare,FASEB channel Medical News Research Results Mouse study reveals synergistic effects from combining drugs that target key epigenetic and DNA repair proteins American Society for Biochemistry and Molecular Biology (ASBMB) Cell Therapy for Brain Tumors: Foundation Hosts Focused Ultrasound Roundtable /articles/cell-therapy-for-brain-tumors-foundation-hosts-focused-ultrasound-roundtable/?sc=c6502 /articles/cell-therapy-for-brain-tumors-foundation-hosts-focused-ultrasound-roundtable/?sc=c6502 Tue, 15 Apr 2025 09:00:45 EST Cell Biology,Clinical Trials,Focused Ultrasound,Immunology,Neuro Medical News Research Results Cell Therapy for Brain Tumors: Foundation Hosts Focused Ultrasound Roundtable Focused Ultrasound Foundation Moffitt-Led International Study Finds New Drug Delivery System Effective Against Rare Eye Cancer /articles/moffitt-led-international-study-finds-new-drug-delivery-system-effective-against-rare-eye-cancer/?sc=c6502 /articles/moffitt-led-international-study-finds-new-drug-delivery-system-effective-against-rare-eye-cancer/?sc=c6502 Thu, 10 Apr 2025 20:20:06 EST All Journal News,Cancer,Clinical Trials,Healthcare,Vision,Top Clipped Stories Medical News Research Results A multi-institutional study led by Moffitt Cancer Center found that percutaneous hepatic perfusion using a melphalan hepatic delivery system may help patients with a rare eye cancer that has spread to their liver. This disease, known as metastatic uveal melanoma, is traditionally very hard to treat and usually has poor outcomes. Moffitt Cancer Center Crystal L. Mackall, MD, FAACR, Recognized with the 2025 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer Immunology /articles/crystal-l-mackall-md-faacr-recognized-with-the-2025-aacr-cancer-research-institute-lloyd-j-old-award-in-cancer-immunology/?sc=c6502 /articles/crystal-l-mackall-md-faacr-recognized-with-the-2025-aacr-cancer-research-institute-lloyd-j-old-award-in-cancer-immunology/?sc=c6502 Thu, 10 Apr 2025 10:50:46 EST Biotech,Cancer,Children's Health,Clinical Trials,Healthcare,Immunology,Public Health Science News Announcement <img src="/legacy/image.php?image=/images/uploads/2025/04/10/67f7daf974154_Email-Crystal-2.jpg&width=100&height=150" alt="Newswise image" />The American Association for Cancer Research (AACR)-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology will be presented to Crystal L. Mackall, MD, Fellow of the AACR Academy, during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago, Illinois. /articles//images/uploads/2025/04/10/67f7daf974154_Email-Crystal-2.jpg Cancer Research Institute Clinical Trial Opens for Patients with High-Grade Neuroendocrine Cancer /articles/clinical-trial-opens-for-patients-with-high-grade-neuroendocrine-cancer/?sc=c6502 /articles/clinical-trial-opens-for-patients-with-high-grade-neuroendocrine-cancer/?sc=c6502 Wed, 09 Apr 2025 20:50:37 EST Biotech,Cancer,Clinical Trials,Healthcare,All Journal News Medical News Clinical Trials <img src="/legacy/image.php?image=/images/uploads/2025/04/09/67f6f26424494_ChauhanAman-04-2025.jpg&width=100&height=150" alt="Newswise image" />A clinical trial for patients with high-grade neuroendocrine tumors is now open for enrollment at Sylvester Comprehensive Cancer Center. The new trial will test the novel combination of immunotherapy paired with a tumor-busting virus. /articles//images/uploads/2025/04/09/67f6f26424494_ChauhanAman-04-2025.jpg Sylvester Comprehensive Cancer Center Stroke Patients Discharged from Hospital Sooner when Administered Revalesio's RNS60; New Statistically Significant Finding from Revalesio's Phase 2 Clinical Trial /articles/stroke-patients-discharged-from-hospital-sooner-when-administered-revalesio-s-rns60-new-statistically-significant-finding-from-revalesio-s-phase-2-clinical-trial/?sc=c6502 /articles/stroke-patients-discharged-from-hospital-sooner-when-administered-revalesio-s-rns60-new-statistically-significant-finding-from-revalesio-s-phase-2-clinical-trial/?sc=c6502 Wed, 09 Apr 2025 09:05:08 EST Clinical Trials,Healthcare,Neuro,Pharmaceuticals Medical News Announcement Results presented during oral presentation at the American Academy of Neurology 2025 Annual Meeting Revalesio Corporation UC San Diego Health Named Region's Only Level 4 Adult Epilepsy Center /articles/uc-san-diego-health-named-region-s-only-level-4-adult-epilepsy-center/?sc=c6502 /articles/uc-san-diego-health-named-region-s-only-level-4-adult-epilepsy-center/?sc=c6502 Tue, 08 Apr 2025 20:25:23 EST Clinical Trials,Drug Resistance,Epilepsy,Healthcare,Neuro,Regenerative Medicine Medical News Expert Pitch <img src="/legacy/image.php?image=/images/uploads/2025/04/08/67f5a059c8e28_Shih-Jerry-UCSDH.jpg&width=100&height=150" alt="Newswise image" /> /articles//images/uploads/2025/04/08/67f5a059c8e28_Shih-Jerry-UCSDH.jpg UC San Diego Health HSS Studies Identify Potential Profile and Treatment Options for Mild Traumatic Brain Injury /articles/hss-studies-identify-potential-profile-and-treatment-options-for-mild-traumatic-brain-injury/?sc=c6502 /articles/hss-studies-identify-potential-profile-and-treatment-options-for-mild-traumatic-brain-injury/?sc=c6502 Tue, 08 Apr 2025 18:00:15 EST Clinical Trials,Healthcare,Neuro Medical News Research Results Two studies by scientists at Hospital for Special Surgery (HSS) offer possible insights into treating mild traumatic brain injury (mTBI), including a potential blood biomarker for injury assessment that could shed light on the role of inflammation, and evidence supporting the use of amitriptyline, historically used as an anti-depressant, but now commonly used for migraine relief, to speed recovery. The research team shared their results today at the American Academy of Neurology 2025 annual meeting. Hospital for Special Surgery Powerful New Tool Promises Major Advances in Cancer Treatment /articles/powerful-new-tool-promises-major-advances-in-cancer-treatment/?sc=c6502 /articles/powerful-new-tool-promises-major-advances-in-cancer-treatment/?sc=c6502 Tue, 08 Apr 2025 12:00:57 EST Cancer,Clinical Trials,Healthcare,Quantum Mechanics,Technology Medical News Research Results <img src="/legacy/image.php?image=https://unisa.edu.au/siteassets/media-centre/images/media-release-images/2025/quantum-probe-1_500x500.jpg&width=100&height=150" alt="Newswise image" />New Australian technology is set to transform the way that gastrointestinal cancers are detected and treated with precise, minimally invasive surgery.Backed by the Federal Government's... /articles/https://unisa.edu.au/siteassets/media-centre/images/media-release-images/2025/quantum-probe-1_500x500.jpg University of South Australia Setback in Gene Therapy for Duchenne Muscular Dystrophy as Immune System Emerges as Key Barrier /articles/setback-in-gene-therapy-for-duchenne-muscular-dystrophy-as-immune-system-emerges-as-key-barrier/?sc=c6502 /articles/setback-in-gene-therapy-for-duchenne-muscular-dystrophy-as-immune-system-emerges-as-key-barrier/?sc=c6502 Tue, 08 Apr 2025 03:45:15 EST Clinical Trials,Genetics,Healthcare,Immunology,Personalized Medicine,Top Hit Stories Medical News Research Results A new paper, published in Gene Therapy, raises serious concerns about the effectiveness of gene therapy for Duchenne muscular dystrophy (DMD), after the treatment failed to show significant benefit in a large-scale clinical trial. University of Portsmouth Clinical Study Shows Modulation of Ki-67 Markers by those taking Avmacol(r) in Former Smokers at High-risk for Lung Cancer /articles/clinical-study-shows-modulation-of-ki-67-markers-by-those-taking-avmacol-in-former-smokers-at-high-risk-for-lung-cancer/?sc=c6502 /articles/clinical-study-shows-modulation-of-ki-67-markers-by-those-taking-avmacol-in-former-smokers-at-high-risk-for-lung-cancer/?sc=c6502 Mon, 07 Apr 2025 21:55:03 EST Cancer,Clinical Trials,Healthcare,Respiratory Diseases and Disorders,Smoking Medical News Research Results Clinical Study Shows Modulation of Ki-67 Markers by those taking Avmacol(r) in Former Smokers at High-risk for Lung Cancer Nutramax Laboratories Test Predicts Which Patients with Prostate Cancer Are Most Likely to Develop Long-Term Side Effects From Radiation Therapy /articles/test-predicts-which-patients-with-prostate-cancer-are-most-likely-to-develop-long-term-side-effects-from-radiation-therapy/?sc=c6502 /articles/test-predicts-which-patients-with-prostate-cancer-are-most-likely-to-develop-long-term-side-effects-from-radiation-therapy/?sc=c6502 Mon, 07 Apr 2025 11:20:58 EST Blood,Cancer,Clinical Trials,Genetics,Healthcare,Top Clipped Stories Medical News Research Results The test, called PROSTOX, is the first of its kind to use microRNAs to predict toxicity from cancer therapy. It could help prevent the burden of long-term complications by identifying patients most at risk before treatment even begins. University of California, Los Angeles (UCLA), Health Sciences